Lenti­Glo­bin con­tin­ues to de­liv­er in lat­est sick­le cell up­date as blue­bird out­lines path to ac­cel­er­at­ed ap­proval, ...

6 years ago
R&D
Cell/Gene Tx

Apel­lis coun­ters Alex­ion’s cri­tique, clears up FDA ques­tions as block­buster de­ci­sion looms

6 years ago
R&D
FDA+

As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

6 years ago
R&D
Pharma

Ver­tex and CRISPR spot­light an­oth­er im­por­tant gene edit­ing ad­vance in a march to a hoped-for cure

6 years ago
R&D
Cell/Gene Tx

Two pre­clin­i­cal biotechs rid­ing the IPO wave this week look to raise $466M-plus; Black­stone's Galakatos backs Rea­ta ...

6 years ago
News Briefing

Take­da con­tin­ues post-Shire sell­off, inch­ing clos­er to $10B goal

6 years ago
Deals

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

6 years ago
Deals
R&D

Fu­eled with a fresh cash in­jec­tion, Cul­li­nan ex­pands its pipeline with a bid to de­vel­op a new com­bi­na­tion drug for ...

6 years ago
R&D

Mod­er­na floors it in­to PhI­II with their Covid-19 vac­cine, plan­ning quick start with a thumbs-up from FDA on tri­al ...

6 years ago
R&D
Coronavirus

At­tor­neys gen­er­al bring an­oth­er ‘col­lu­sion’ case against gener­ic mak­ers, nam­ing No­var­tis and Pfiz­er among over a ...

6 years ago
Pharma

Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

6 years ago
Coronavirus

A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO

6 years ago
Financing
China

Juno, WuXi JV in Chi­na score $100M in fresh fund­ing as it sets stage for first CAR-T ap­proval

6 years ago
Financing
China

Pe­ter Marks dish­es on Covid-19 vac­cine de­vel­op­ment at BIO

6 years ago
FDA+
Coronavirus

'Tremen­dous' an­i­mal da­ta in­spire GV, ARCH's $63M boost­er for Sekar Kathire­san's dri­ve to rel­e­gate coro­nary heart ...

6 years ago
Financing

Pfiz­er of­fers 3rd round of JAK da­ta, this time in kids. Can it com­pete?

6 years ago
R&D

Rare dis­ease start­up NFlec­tion scores $20M in Se­ries A haul; Gilead part­ner Gala­pa­gos signs pact with Ox­ford biotech

6 years ago
News Briefing

Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

6 years ago
Deals
China

Fu­ji­film dou­bles down on ex-Bio­gen fa­cil­i­ty with $928M in­fu­sion as biotech boom fu­els CD­MO growth

6 years ago
Outsourcing

IPO bound? Five years in, Art Krieg and the Check­mate crew col­lect $85M to back up their 1-drug pipeline

6 years ago
Financing

De­nali scoots past a set­back with bare­ly a scratch, quick­ly call­ing up a back­up Alzheimer’s play­er on the bench

6 years ago
R&D

Har­vard's Charles Lieber in­dict­ed for ly­ing to the feds, bring­ing US re­searcher­s' Chi­na ties back to the spot­light

6 years ago
People
China

Covid-19 roundup: Fau­ci talks pric­ing, dis­parate im­pact and the virus’s en­dur­ing mys­ter­ies; Chi­na to of­fer ...

6 years ago
R&D
Coronavirus

Ab­b­Vie’s patent-ag­gres­sive US strat­e­gy for flag­ship Hu­mi­ra pays off, as judge dis­miss­es law­suit al­leg­ing ...

6 years ago
Pharma
First page Previous page 833834835836837838839 Next page Last page
A service from the Financial Times